Salt Lake City – at the 2018 BMT Tandem meeting (Twitter: #BMTTandem18) the combined annual meeting of the American Society for Blood and Marrow Transplantation (ASBMT) and Center for International Blood & Marrow Transplant Research (CIBMTR), one of the presentations of note today was a 7am breakfast symposium entitled:

“Realizing the Promise of CAR T cell Therapy for Leukemia and Lymphoma: Implications for Long-term Care in the Era of Stem Cell Transplantation.”

Cancer cells in culture Source: Dr Cecil Fox, National Cancer Institute

This educational session supported by grants from Kite/Gilead and Novartis, featured two BMT transplant experts with hands-on experience of CAR T cell trials: Dr Stephan Grupp (@GruppSteve) from The Children’s Hospital of Philadelphia and Dr Krishna Komanduri (@drkomanduri) from the University of Miami Sylvester Comprehensive Cancer Center.

We’ve previously interviewed both Dr Grupp and Dr Komanduri on BSB, so were keen to hear how leading transplanters view the CAR T landscape now that two therapies have been approved by the FDA, and how they think this approach will integrate with transplants, and which patients will benefit most from this therapy.

Subscribers can log-in to read the take-homes we took from this session or if you didn’t make it to Salt Lake City, can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by